ArticleAsian journal of pharmaceutical sciences2022
Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant
Article in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Nanotechnology-Enabled Antibiotic Therapy: The Promise of Transfersomal Tigecycline in Combating Methicillin-ResistantCurrent drug delivery · 2026Article
- Dual Antibiotic-Infused Liposomes to Control Methicillin-ResistantMedicines (Basel, Switzerland) · 2025Article
- A Tea Polyphenol-Infused Sprayable Thermosensitive Liposomal Hydrogel for Enhanced Anti-Inflammatory and Antibacterial Psoriasis Treatment.Journal of functional biomaterials · 2025Article
- Immunomodulation in Non-traditional Therapies for Methicillin-resistant Staphylococcus aureus (MRSA) Management.Current microbiology · 2024Review
- Photoresponsive Multirole Nanoweapon Camouflaged by Hybrid Cell Membrane Vesicles for Efficient Antibacterial Therapy of Pseudomonas aeruginosa-Infected Pneumonia and Wound.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Transforming Medicine with Nanobiotechnology: Nanocarriers and Their Biomedical Applications.Pharmaceutics · 2024Review
- Charge adaptive phytochemical-based nanoparticles for eradication of methicillin-resistant staphylococcus aureus biofilms.Asian journal of pharmaceutical sciences · 2024Article
- Liposomal Rifabutin-A Promising Antibiotic Repurposing Strategy against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Daptomycin Liposomes Exhibit Enhanced Activity against Staphylococci Biofilms Compared to Free Drug.Pharmaceutics · 2024Article
- Recent advances in nanostructured delivery systems for vancomycin.Nanomedicine (London, England) · 2024Review
- Innovative Phospholipid Carriers: A Viable Strategy to Counteract Antimicrobial Resistance.International journal of molecular sciences · 2023Review
- Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.Asian journal of pharmaceutical sciences · 2023Review
- Regulation ofPharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focused on the encapsulation of vancomycin (VAN) into liposomes coated with a red blood cell membrane with a targeting ligand, daptomycin-polyethylene glycol-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, formed by conjugation of DAPT and N-hydroxysuccinimidyl-polyethylene glycol-1,2-distearoyl-sn-glycero-3-phosphoethanolamine. This formulation is capable of providing controlled and targeted drug delivery to the bacterial cytoplasm. We performed MALDI-TOF, NMR and FTIR analyses to confirm the conjugation of the targeting ligand via the formation of amide bonds. Approximately 45% of VAN could be loaded into the aqueous cores, whereas 90% DAPT was detected using UV-vis spectrophotometry. In comparison to free drugs, the formulations controlled the release of drugs for > 72 h. Additionally, as demonstrated using CLSM and flow cytometry, the resulting formulation was capable of evading detection by macrophage cells. In comparison to free drugs, red blood cell membrane-DAPT-VAN liposomes, DAPT liposomes, and VAN liposomes reduced the MIC and significantly increased bacterial permeability, resulting in > 80% bacterial death within 4 h. Cytotoxicity tests were performed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.